the Role of Technology in Elderly Patients (SILVER)
Fighting Against Social Isolation in Times of Pandemic Corona Virus-19: the Role of Technology in Elderly Patients: The SILVER Study
Starting from December 2019, the Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-COV-2) disease spread rapidly from China into the world, with about two Mio cases confirmed around the world. In Switzerland, more than 26'000 cases have been confirmed so far, and health authorities declared in March the needs for social isolation and have banned visits to hospitalized patients and to nursing home residents. Loneliness and isolation is a significant concern for the elderly patients as well as for their families that may significantly affect physical and mental health in both.
SILVER aims to evaluate the role of programmed video calls with families:
- on mood, anxiety, fear of death and pain perception in patients hospitalized or in nursing homes during the SARS-COV-2 pandemic.
- in relieving the familiar caregiver anxiety and fear of death of others
- in relieving the professional caregiver anxiety.
SILVER is an international study involving both acute, rehabilitation geriatric units and nursing homes; we will enroll all the patients present in the participating centers. Patients will be allowed to chose between video and phone calls, the following dimensions will be evaluated:
- Delirium risk: using the Confusion Assessment Method (CAM)
- Mood: using the 5-item Geriatric Depression Scale (GDS)
- Anxiety: using the Clinical Anxiety Scale (GAS).
- Fear of death (self and others): using the Collett-Lester scale. In parallel, health professionals and family caregivers will be evaluated for anxiety at baseline and every week after intervention set-up by the Clinical Anxiety Scale (CAS). Family caregivers will also be evaluated with the fear of death scale (sub-scale fear of death of others).
Finally, to evaluate the appreciation for video call communication in patients and caregivers we will use a Likert scale.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Aims.
- To evaluate the role of video calls with families on mood, anxiety, fear of death and pain perception in patients hospitalized or in nursing homes during the SARS-CoV-2 pandemic.
- To evaluate the role of video calls in relieving family caregivers' anxiety and fear of death of their loved one.
- To evaluate the role of video calls in relieving health professionals' anxiety.
Methods. In order to reduce social isolation from their relatives and friends patients will be helped in joining them through video-calls thanks to the use of dedicated tablets and to the assistance provided by nurses, assistant-nurses, occupational therapists or neuropsychologists.
Population selection. All the patients in the participating centers fulfilling inclusion/exclusion criteria will be enrolled in SILVER.
Patients will be asked to chose between video and phone call, phone call will be allowed without any restriction to both video and usual care groups.
standardization of video calls: Two video-calls of maximum 15' will be administered every week; in addition, patients will be allowed to do video-call upon request. Video-calls will be performed using Skype or WhatsApp video or Face-time, the use of others app will be evaluated upon family's request.
Data collection for primary and secondary outcomes. Patients will be evaluated at baseline and every week with standardized scales to assess their mood, anxiety and delirium symptoms.
At baseline and at the end of the intervention we will evaluate the overall appreciation of the video call by the patients, their family caregiver, and the health professionals using a Likert scale and Anxiety: using the Geriatric Anxiety Scale (GAS).
In order to clarify the role of social connection through video calls on the patients' health, we will evaluate at baseline and after one week :
- Mood: using the 5-items Geriatric Depression Scale (GDS-5)
- Fear of death (self and others): using the Collett-Lester scale
- Delirium risk: using the Confusion Assessment Method (CAM) will be evaluated every day and will be analyzed ad day of delirium weekly.
In addition, the effect of video calls in professionals and in family caregivers will be evaluated as follows:
family and professional caregivers will be evaluated for anxiety at baseline and the end of intervention set-up by the Clinical anxiety (CAS). Familiar care-givers will also be evaluated with the fear of death scale (sub-scale fear of death of others) at the baseline and after one week.
Collection of other data.
In order to correct the statistical analyses for possible confounding variables the following data will be collected:
Age, gender, years of school, duration of hospitalization , type of hospital discharge, Mini Mental State Examination (MMSE), Clinical Dementia Rating (CDR) scale, Cumulative Illness Rating Scale (CIRS) index, Activity of Daily Living (ADL), Instrumental Activities of Daily Living (IADL).
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Lausanne, Suíça, 1012
- Patrizia D'amelio
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- patients of 65 years and older hospitalized in the participating unit during the absence of visits due to the SARS-CoV2 pandemic.
- Patients and families willing to participate.
Exclusion Criteria:
- patients or families who refuse to participate.
- Clinical Dementia Rating (CDR) equal or higher than two.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
phone calls
patients choosing phone calls as preferred communication technique
|
A tablet for video-calls will be available for patients and families.
Two video-calls of maximum 15' will be organized every week; in addition, patients will be allowed to do video-call upon request.
Video-calls will be performed using Skype or WhatsApp video or Face-time
Outros nomes:
|
|
video call
patients choosing video calls as preferred communication technique
|
A tablet for video-calls will be available for patients and families.
Two video-calls of maximum 15' will be organized every week; in addition, patients will be allowed to do video-call upon request.
Video-calls will be performed using Skype or WhatsApp video or Face-time
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
4-point likert scale (LKRT)
Prazo: 0-7 days
|
appreciation of video calls by patients and families rage 0-4, 4 represent the better outcome
|
0-7 days
|
|
Geriatric anxiety scale (GAS-10)
Prazo: 0-7 days
|
measure of anxiety, The GAS-10 form, contains a total of 10 items, the answers are yes or no and the possible scores range from 0 to 10, with a cut-off point for anxiety at 6.
The higher the score, the greater the anxiety.
|
0-7 days
|
|
Collett Lester Fear of Death scale (CL-FOD) for self and others
Prazo: 0-7 days
|
fear of death scale of patients, The CL-FODS contains 28 items, with seven items on each of the four subscales: Fear of Death of Self, Dying of Self, Death of Others, and Dying of Others.
It is answered on a 5-point Likert format anchored as follows: 1 (not) and 5 (very).
The total score in each subscale could range from 7 to 35, with higher scores denoting higher anxiety from death or dying.
|
0-7 days
|
|
geriatric depression scale (GDS-5)
Prazo: 0-7 days
|
mood evaluation for patients.
the GDS-5 contains 5 items, the total score range from 0 to 5, the clinical cut-off for suspicion of depression is 2
|
0-7 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Collett Lester Fear of Death scale (CL-FOD) for others
Prazo: 0-7 days
|
fear of death scale of others for family
|
0-7 days
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2020-01125
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .